It's been more than three years since Amgen's ($AMGN) multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech. Earlier this month, it picked up a new competitor in its home market in Johnson & Johnson's ($JNJ) Darzalex. And though that med will come after both Kyprolis and Celgene rival Pomalyst in the disease course, J&J will be armed with data showing that 36% of patients responded to the top dose of Darzalex in a small study, a number that tops Kyprolis' 23%. More from FiercePharmaMarketing